- Home
- VYNE vs CASI Comparison
VYNE vs CASI Comparison
Compare VYNE & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VYNE | CASI |
|---|---|---|
| Founded | 2003 | 1991 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 19.7M |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | VYNE | CASI |
|---|---|---|
| Price | $0.59 | $0.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 418.2K | 26.1K |
| Earning Date | 03-05-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $524,000.00 | ★ $26,846,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.29 | ★ 21.72 |
| 52 Week Low | $0.28 | $0.74 |
| 52 Week High | $2.94 | $3.09 |
Technical Indicators
Market Signals| Indicator | VYNE | CASI |
|---|---|---|
| Relative Strength Index (RSI) | 68.94 | 38.96 |
| Support Level | $0.55 | $0.74 |
| Resistance Level | $0.57 | $0.97 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 91.01 | 19.74 |
Price Performance
Historical ComparisonAbout VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.